ES2773103T3 - Formulación de anticuerpos anti HER2 - Google Patents
Formulación de anticuerpos anti HER2 Download PDFInfo
- Publication number
- ES2773103T3 ES2773103T3 ES13808043T ES13808043T ES2773103T3 ES 2773103 T3 ES2773103 T3 ES 2773103T3 ES 13808043 T ES13808043 T ES 13808043T ES 13808043 T ES13808043 T ES 13808043T ES 2773103 T3 ES2773103 T3 ES 2773103T3
- Authority
- ES
- Spain
- Prior art keywords
- formulation
- her2
- antibody
- her2 antibody
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745293P | 2012-12-21 | 2012-12-21 | |
PCT/EP2013/077166 WO2014096051A1 (fr) | 2012-12-21 | 2013-12-18 | Préparation d'anticorps anti-her2 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2773103T3 true ES2773103T3 (es) | 2020-07-09 |
Family
ID=49779926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13808043T Active ES2773103T3 (es) | 2012-12-21 | 2013-12-18 | Formulación de anticuerpos anti HER2 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20150343058A1 (fr) |
EP (1) | EP2934582B1 (fr) |
JP (2) | JP6400595B2 (fr) |
AU (1) | AU2013360812B2 (fr) |
BR (1) | BR112015014853A2 (fr) |
CA (1) | CA2895869C (fr) |
DK (1) | DK2934582T3 (fr) |
EA (1) | EA201391729A1 (fr) |
ES (1) | ES2773103T3 (fr) |
HK (1) | HK1215796A1 (fr) |
IL (1) | IL239509A0 (fr) |
MX (2) | MX367748B (fr) |
PL (1) | PL2934582T3 (fr) |
SG (1) | SG11201504897YA (fr) |
WO (1) | WO2014096051A1 (fr) |
ZA (1) | ZA201504564B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
BR112021015034A2 (pt) | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | Formulação de anticorpo terapêutico |
AR119293A1 (es) | 2019-06-28 | 2021-12-09 | Genentech Inc | Composición y métodos para estabilizar formulaciones líquidas de proteínas |
EP3999537A1 (fr) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Formulation d'anticorps lyophilisée |
CN115175737A (zh) | 2020-02-28 | 2022-10-11 | 瑞泽恩制药公司 | 结合her2的双特异性抗原结合分子及其使用方法 |
CN114762727A (zh) * | 2021-01-15 | 2022-07-19 | 海正生物制药有限公司 | 一种稳定的帕妥珠单抗的药物组合物 |
WO2023140807A1 (fr) * | 2022-01-19 | 2023-07-27 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions pharmaceutiques de trastuzumab |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03504605A (ja) * | 1988-05-27 | 1991-10-09 | セントカー・インコーポレーテツド | 抗体産生物の凍結乾燥した配合物 |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
DK2275119T3 (da) * | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
DE69810481T2 (de) * | 1997-06-13 | 2003-09-25 | Genentech Inc | Stabilisierte antikörperformulierung |
US7452539B2 (en) * | 2001-12-19 | 2008-11-18 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
US20060182740A1 (en) * | 2002-06-21 | 2006-08-17 | Biogen Idec, Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2390267B1 (fr) * | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Anticorps stables et solubles inhibant le TNF (alpha) |
KR20080031684A (ko) * | 2005-06-14 | 2008-04-10 | 암젠 인코포레이티드 | 자가 - 완충성 단백질 제형 |
US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
-
2013
- 2013-12-18 MX MX2015008194A patent/MX367748B/es active IP Right Grant
- 2013-12-18 US US14/654,096 patent/US20150343058A1/en not_active Abandoned
- 2013-12-18 EP EP13808043.7A patent/EP2934582B1/fr active Active
- 2013-12-18 PL PL13808043T patent/PL2934582T3/pl unknown
- 2013-12-18 CA CA2895869A patent/CA2895869C/fr active Active
- 2013-12-18 AU AU2013360812A patent/AU2013360812B2/en not_active Ceased
- 2013-12-18 DK DK13808043.7T patent/DK2934582T3/da active
- 2013-12-18 WO PCT/EP2013/077166 patent/WO2014096051A1/fr active Application Filing
- 2013-12-18 ES ES13808043T patent/ES2773103T3/es active Active
- 2013-12-18 JP JP2015548495A patent/JP6400595B2/ja not_active Expired - Fee Related
- 2013-12-18 BR BR112015014853A patent/BR112015014853A2/pt not_active Application Discontinuation
- 2013-12-18 SG SG11201504897YA patent/SG11201504897YA/en unknown
- 2013-12-19 EA EA201391729A patent/EA201391729A1/ru unknown
-
2015
- 2015-06-18 IL IL239509A patent/IL239509A0/en unknown
- 2015-06-22 MX MX2019010479A patent/MX2019010479A/es unknown
- 2015-06-24 ZA ZA2015/04564A patent/ZA201504564B/en unknown
-
2016
- 2016-04-01 HK HK16103770.2A patent/HK1215796A1/zh unknown
-
2018
- 2018-09-05 JP JP2018165536A patent/JP2018199720A/ja active Pending
-
2019
- 2019-07-08 US US16/504,411 patent/US20200061190A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014096051A1 (fr) | 2014-06-26 |
PL2934582T3 (pl) | 2020-08-10 |
CA2895869C (fr) | 2020-09-22 |
US20200061190A1 (en) | 2020-02-27 |
DK2934582T3 (da) | 2020-02-24 |
ZA201504564B (en) | 2016-11-30 |
AU2013360812A1 (en) | 2015-07-09 |
EP2934582A1 (fr) | 2015-10-28 |
CA2895869A1 (fr) | 2014-06-26 |
MX2019010479A (es) | 2019-10-15 |
SG11201504897YA (en) | 2015-07-30 |
EA201391729A1 (ru) | 2014-09-30 |
US20150343058A1 (en) | 2015-12-03 |
AU2013360812B2 (en) | 2018-11-08 |
WO2014096051A9 (fr) | 2014-10-02 |
HK1215796A1 (zh) | 2016-09-15 |
MX2015008194A (es) | 2016-02-05 |
JP2018199720A (ja) | 2018-12-20 |
IL239509A0 (en) | 2015-08-31 |
JP2016508973A (ja) | 2016-03-24 |
JP6400595B2 (ja) | 2018-10-03 |
MX367748B (es) | 2019-09-04 |
EP2934582B1 (fr) | 2019-11-27 |
BR112015014853A2 (pt) | 2017-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2773103T3 (es) | Formulación de anticuerpos anti HER2 | |
JP7483376B2 (ja) | プログラム死受容体1(pd-1)抗体の安定製剤およびその使用方法 | |
CN108367072B (zh) | 含抗-pd-l1抗体avelumab的水性药物制剂 | |
ES2925992T3 (es) | Formulaciones estables de polipéptidos | |
ES2751659T3 (es) | Formulación de anticuerpos | |
EP2648750B1 (fr) | Formulation d'anticorps | |
KR101782203B1 (ko) | 동결건조 및 수성 항-cd40 항체 제제 | |
ES2866050T3 (es) | Composiciones que comprenden conjugados de anticuerpos-fármaco duocarmicina | |
RU2653447C2 (ru) | Стабилизированные содержащие антитела жидкие композиции | |
JP7473603B2 (ja) | 液体医薬組成物 | |
US20100260766A1 (en) | Stable antibody formulations | |
ES2910443T3 (es) | Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol | |
US20200190179A1 (en) | Protein solution formulation containing high concentration of an anti-vegf antibody | |
JP2018531980A (ja) | 抗d因子抗体製剤 | |
JP2023549776A (ja) | 医薬製剤 | |
BR112021009548A2 (pt) | composição líquida estável que compreende proteína | |
CN118119377A (zh) | 制剂 |